Breaking News

Coriolis Pharma Expands ATMP Development Facilities

Construction of new facilities for ATMP formulation development up to biosafety level S2 are in progress and operations are expected to start by 4Q21.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Coriolis Pharma, a provider of research and development of for (bio)pharmaceutical drugs, is expanding its advanced therapy medicinal products (ATMP) development facilities under biosafety level S2 (BSL2 / S2).   Re-construction of an existing building near the Coriolis headquarters started in March this year and the laboratories are planned to be operational in the fourth quarter of 2021. The new facilities will increase Coriolis’ total floor space to 7,800 square meters. The new labs will ho...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters